2017-10 INN Report - European Medicines Agency - Europa EU
Recommend Documents
Jan 4, 2018 - Information Management Division. Applications for new human medicines under evaluation by the Committee fo
Jun 23, 2016 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic
Nov 28, 2017 - Information Management Division. Applications for new human medicines under evaluation by the Committee f
Jun 14, 2018 - IS/1/15/020/01. NOVARTIS HEALTHCARE A/S IS. Ritalin, tabletten 10 mg not available. RVG 03957. NOVARTIS P
May 4, 2018 - Information Management Division ... The information in this report was compiled on 4 May 2018. Information
May 17, 2018 - ... authorised medicinal products. Active substance(s): latanoprost (products with paediatric indication)
Apr 5, 2018 - 1 i Based on the ATC therapeutic sub-group. Orphan medicinal products. International non-proprietary name
Oct 20, 2016 - identifies key priorities which will need to be implemented in the coming years to 2020. .... European Me
May 22, 2014 - weight was found to be superior to using body surface area (BSA) effect ... The population median BSA of
Mar 17, 2011 - Marketing authorisation holder: ..... Data from the Health Protection Agency (HPA) in the UK affords an additional opportuni ..... assay was modified by simplification of some of the assay steps and by introduction of automation.
Dec 16, 2009 - negative trend, should be reported to the Rapporteur and the EMA. ...... If the primary joint met the pri
Feb 21, 2013 - confidential nature deleted. 7 Westferry Circus .... confirmatory data to support an extension to the ind
Considering the above data, bortezomib is not expected to ...... For the integrated data, 1,353 of 1,572 (86%) randomise
Oct 20, 2016 - In order to ensure that scientific and technical advances efficiently contribute to .... to rate their le
Jun 16, 2016 - EU Medicines Agencies Network Strategy to 2020 . ..... Involvement of patients and consumers at a Member
Feb 5, 2016 - testing in the Rocket AF and J Rocket studies. The Rocket AF .... On October 08, 2015 Alere sent an email
Jul 1, 2015 - highlights newsletter' and then click on 'Subscribe to this feed'. .... granted a conditional marketing au
E-mail: [email protected] http://www.ema.europa.eu ... defects result in impaired bone formation, increased bone fragil
May 22, 2014 - Response Evaluation Criteria in Solid Tumours ...... Pancreatitis and disseminated intravascular coagulat
2017-10 INN Report - European Medicines Agency - Europa EU
Oct 5, 2017 - EMA/661972/2017. Information Management Division. Applications for new human medicines under evaluation by
5 October 2017 EMA/661972/2017 Information Management Division
Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use October 2017
This document lists information on applications for centralised marketing authorisation for human medicines that the European Medicines Agency has received for evaluation. It includes the international non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation by the Committee for Medicinal Products for Human Use (CHMP). For generic and biosimilar medicines, it includes the INN (active moiety only, with no information on salt, ester or derivative) and therapeutic area. This list only includes information for medicines whose applications have been validated at the time the report was compiled. The information in this report was compiled on 4 Oct 2017. Information on designated orphan medicines that are being assessed for marketing authorisation is also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP). Information in bold corresponds to new entries in the monthly list. Entries are removed from this list once the medicine has received a positive or negative opinion from the CHMP or when the applicant has withdrawn the application. The Agency publishes information on these opinions and withdrawn applications on its website. Information on CHMP opinions is also published in the monthly CHMP highlights.
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact
![Invokana, INN-canagliflozin - European Medicines Agency - Europa EU [PDF]](https://m.moam.info/img/260x300/invokana-inn-canagliflozin-european-medicines-agen_64900894098a9e001a8b45d5.jpg)
